The group’s principle activities include discovering and developing small-molecule kinase inhibitors for the treatment of cancer. The group’s technology includes KINOMEscan(TM) technology. The group’s products include FLT3 Kinase, AURORA Kinase and BRAF Kinase. The group operates from United States.